Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shunsuke Mori

Showing results (1-10 of 152) with videos related to

Pageof 16
Sort By:
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|September 25, 2015
Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary FibrosisShunsuke Mori
Modern Rheumatology|April 30, 2011
Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugsShunsuke Mori
Modern Rheumatology|April 18, 2007
A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapyShunsuke Mori
Modern Rheumatology|February 22, 2012
Additional use of tacrolimus after switching to tocilizumab therapy in patients with primary lack of efficacy of infliximab therapy for rheumatoid arthritisShunsuke Mori
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|September 8, 2020
Leukocytapheresis for rheumatoid arthritis cases that are super-resistant to any class of biological drugs and tofacitinibShunsuke Mori
The Journal of Rheumatology|June 5, 2012
Do low titers of antibody against hepatitis B surface antigen carry a risk of viral reactivation during immunosuppressive therapy for rheumatic diseases?Shunsuke Mori
Statistics in Medicine|August 6, 2020
Comment on: A review of the use of time-varying covariates in the Fine-Gray subdistribution hazard competing risk regression model by Peter C. Austin, Aurélien Latouche, and Jason P. FineShunsuke Mori
Rheumatology (Oxford, England)|September 15, 2012
Comment on: Tocilizumab treatment in a patient suffering from rheumatoid arthritis and concomitant chronic hepatitis C infectionShunsuke Mori, Shigetoshi Fujiyama
Clinical Rheumatology|August 11, 2019
Outcomes of dose reduction, withdrawal, and restart of tofacitinib in patients with rheumatoid arthritis: a prospective observational studyShunsuke Mori, Yukitaka Ueki
Clinical Rheumatology|December 16, 2011
Is continuation of anti-tumor necrosis factor-α therapy a safe option for patients who have developed pulmonary mycobacterial infection? : Case presentation and literature reviewShunsuke Mori, Mineharu Sugimoto
Pageof 16

Showing results (1-10 of 152) with videos related to

Sort By:
Pageof 16
Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine|September 25, 2015
Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary FibrosisShunsuke Mori
Modern Rheumatology|April 30, 2011
Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugsShunsuke Mori
Modern Rheumatology|April 18, 2007
A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapyShunsuke Mori
Modern Rheumatology|February 22, 2012
Additional use of tacrolimus after switching to tocilizumab therapy in patients with primary lack of efficacy of infliximab therapy for rheumatoid arthritisShunsuke Mori
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|September 8, 2020
Leukocytapheresis for rheumatoid arthritis cases that are super-resistant to any class of biological drugs and tofacitinibShunsuke Mori
The Journal of Rheumatology|June 5, 2012
Do low titers of antibody against hepatitis B surface antigen carry a risk of viral reactivation during immunosuppressive therapy for rheumatic diseases?Shunsuke Mori
Statistics in Medicine|August 6, 2020
Comment on: A review of the use of time-varying covariates in the Fine-Gray subdistribution hazard competing risk regression model by Peter C. Austin, Aurélien Latouche, and Jason P. FineShunsuke Mori
Rheumatology (Oxford, England)|September 15, 2012
Comment on: Tocilizumab treatment in a patient suffering from rheumatoid arthritis and concomitant chronic hepatitis C infectionShunsuke Mori, Shigetoshi Fujiyama
Clinical Rheumatology|August 11, 2019
Outcomes of dose reduction, withdrawal, and restart of tofacitinib in patients with rheumatoid arthritis: a prospective observational studyShunsuke Mori, Yukitaka Ueki
Clinical Rheumatology|December 16, 2011
Is continuation of anti-tumor necrosis factor-α therapy a safe option for patients who have developed pulmonary mycobacterial infection? : Case presentation and literature reviewShunsuke Mori, Mineharu Sugimoto
Pageof 16